Key result
Long-term N-acetylprocainamide reduces PVC frequency and normalizes PEP/LVET versus placebo.
Why the study?
Does long-term N-acetylprocainamide therapy improve PVC frequency and left ventricular function in patients with chronic PVCs?
Population
6 patients with chronic premature ventricular complexes (PVCs) known to respond to N-acetylprocainamide (NAPA)
Comparison
Long-term N-acetylprocainamide (NAPA) therapy vs Placebo
Design
Case_series
Follow-up
1 year
Authors
Loading...
May support N-acetylprocainamide evaluation in chronic PVCs; leaves open confirmation in prospective trials.
Does long-term N-acetylprocainamide therapy improve PVC frequency and left ventricular function in patients with chronic PVCs?
Long-term N-acetylprocainamide therapy appears well tolerated with a low rate of abnormal ANA titers, and may improve underlying PVC frequency and left ventricular function over one year.
Lertora et al. (1979) studied chronic PVCs (n=6). N-acetylprocainamide (NAPA) vs. placebo was evaluated on PVC frequency and PEP/LVET. Long-term N-acetylprocainamide therapy in 6 patients with chronic PVCs reduced placebo-period PVC frequency and normalized PEP/LVET after one year, with abnormal ANA titers in only 1 patient.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: